Osteoporosis International

, Volume 21, Issue 11, pp 1963–1964 | Cite as

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab

  • K. A. ToulisEmail author
  • A. D. Anastasilakis


Public Health Breast Cancer Confidence Interval Osteoporosis Risk Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflicts of interest



  1. 1.
    Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMedGoogle Scholar
  2. 2.
    Anastasilakis AD, Toulis KA, Goulis DG et al (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41(10):721–729CrossRefPubMedGoogle Scholar
  3. 3.
    Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 20, 26(30):4875–4882Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  1. 1.Division of Endocrinology and Metabolism, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Division of Endocrinology & Metabolism424 General Military HospitalThessalonikiGreece

Personalised recommendations